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Abstract 
 
Objective To study the stability and emergence of a range of Behavioural and 
Psychological Symptoms (BPS), their association with mortality and the effect of 
covariates on these transitions in a population based study of cognitively impaired older 
people with a long follow-up period and large sample size, with a particular focus on 
apathy.  
Methods Data were from a population-based, longitudinal cohort study of ageing. 
Interviews were conducted at 0, 2, 6, 8 and 10 years with 3,626 participants  aged 65+. 
The persistence of 11 BPS and their association with mortality in those with cognitive 
impairment (MMSE 25 or below) was investigated using multistate models, allowing us to 
take into account estimations of the probability of transitions that occurred in the time 
between interviews. 
Results Most BPS were persistent. Apathy was one of the most stable symptoms; in those 
with apathy, the probability of still having apathy after 1 year is 62%. Apathy, sleep 
problems, depression, irritability and wandering were most likely to develop. BPS are 
associated with mortality; in those with apathy mortality is 3.1 times more likely than in 
those without apathy. Low cognitive function and dementia were associated with 
emergence of new symptoms.  
Conclusions This population-based, multi-centre study with a follow-up period of 10 
years showed that BPS are associated with mortality and most symptoms are persistent. 
Apathy was characterised by a high prevalence, a high persistence and a strong 
association with mortality, and has a negative impact on disability, management of other 
disease and caregiver burden.   
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Objective 
 
Behavioural and Psychological Symptoms (BPS) are present in over 80% of people with 
dementia  (Garre-Olmo et al. 2010; Lyketsos et al. 2002; Steinberg et al. 2008; Zuidema et 
al. 2007), and are also common in those without dementia and in those with mild 
cognitive impairment (Monastero et al. 2009; Savva et al. 2009; van der Linde et al. 
2010). In order to design and conduct clinical trials for the treatment of BPS, more 
information about the pattern of BPS over the course of dementia is needed to identify 
the best stage to intervene.  
We have recently performed a systematic review of the longitudinal course of BPS (under 
review with the British Journal of Psychiatry). Most studies have recruited participants 
from psychiatric services, which have obvious sources of bias. Population-based studies 
were limited to looking at depression and most did not study the stability of symptoms, 
so data regarding the incidence and persistence of other common and important BPS, 
such as apathy, elation and wandering, are lacking.  
 
This study overcomes many of the limitations of previous studies by studying a 
population-based sample (the Medical Research Council Cognitive Function and Ageing 
Study, MRC-CFAS) of over 3,500 participants aged 65 years and over with a prospective 
follow-up of 10 years. Eleven symptoms were studied: apathy, depression, anxiety, 
irritability, agitation, hallucination, persecution, misidentification, sleep problems, 
wandering and elation. Using a multistate model makes it possible to take into account 
estimations of the probability of transitions that occurred in the time between 
interviews. 
 
Although, conventionally, BPS are just studied in the context of dementia, it is important 
to consider that some BPS may appear before the onset of or the diagnosis of dementia, 
and therefore the continuities ‘before’ and ‘after’ dementia are important to study. BPS 
in a cognitively healthy older person may indicate early dementia, and certain BPS, for 
example, depression, may indeed be risk factors for dementia. Common biological and 
psychosocial risk factors for BPS may exist among the cognitively healthy and cognitively 
impaired older populations. Therefore, we included all participants with cognitive 
impairments (MMSE<25) with or without dementia.  
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We aimed to study the stability and emergence of a range of BPS, the association of BPS 
with mortality and the effect of covariates on these transitions in cognitively impaired 
older people.  
 
Methods 
 
Sample 
 
Data were from the Medical Research Council Cognitive Function and Ageing Study (MRC 
CFAS), a multicentre longitudinal population-based study of ageing  (Brayne et al. 2006). 
Participants aged 65 years and over were randomly selected from the Family Health 
Service Authority lists in two rural centres in Cambridgeshire and Gwynedd, and four 
urban centres in Liverpool, Newcastle, Nottingham and Oxford in the UK. 
 
Screening interviews were conducted at baseline and two years. Individuals were 
randomly sampled into assessment interviews at both baseline and two years. The 
assessment interviews with participants and informal caregivers were completed at 
baseline and after 2, 6, 8 and 10 years follow-up as shown in Online Additional Figure 1. 
As some participants entered the study at one of the later interviews (due to the 
sampling into assessment interviews) and as in Liverpool (Saunders et al. 1993) an 
additional interview was conducted 2 years before the study started in the other 5 
centres, the interviews are described as ‘first interview’, ‘second interview’, ‘third 
interview’, ‘fourth interview’, and ‘fifth interview’.    
 
Participants with a baseline Mini Mental State Examination (MMSE) score of 26 or higher 
(n=2,134) were excluded from analyses, as well as participants with a single interview 
only for whom therefore no transitions were recorded (shown in Online Additional Table 
1, for apathy: n=72).  
 
BPS and covariates 
 
Apathy, depression, anxiety, irritability, agitation, hallucination, persecution, 
misidentification, sleep problems, wandering and elation were measured using the 
Geriatric Mental State (GMS) Automated Geriatric Examination for Computer-Assisted 
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Taxonomy  (AGECAT) and Cambridge Mental Disorders of the Elderly Examination 
(CAMDEX) interviews with participants and informants as previously described by Savva 
et al. (Savva et al. 2009).   
 
It has been previously shown that age, sex, cognitive function and dementia are 
associated with BPS and mortality and these variables were taken into account as 
covariates.  Age was recorded at each interview.  Only baseline cognitive function and 
dementia status were taken into account, as time varying covariates require a much more 
complex model with a much larger dataset. Baseline cognitive function was measured 
with the Mini Mental State Examination (MMSE). Scores were categorised in low (MMSE 
0-18), moderate (MMSE 19-22) and high (MMSE 23-25) using previously defined cut-off 
scores (Huppert et al. 2005; Matthews et al. 2008; Stephan et al. 2010). Dementia status 
was derived using the full GMS-AGECAT diagnostic algorithm (Copeland et al. 1986). 
 
BPS information at previous interviews was combined in a measure of BPS history. 
Reporting presence of BPS at one or more of the previous interviews was compared to 
never reporting BPS at the previous interviews. BPS history was not available at baseline.  
 
Mortality 
 
Date of death until 31 December 2006 was recorded for all participants based on 
information from the Office for National Statistics National Health Service Central 
Register.  Participants who were alive at this time were censored, i.e. they are known to 
be alive but in an unknown state.  
 
Statistical methods 
 
The stability of BPS and their association with mortality was investigated using multi-state 
models. A multi-state Markov model is a way of describing the process in which an 
individual moves through a series of states in continuous time.  It models death, decline 
and recovery within the same model and allows covariate effects to vary for each 
transition. The transitions between the following three states were analysed: “no 
symptom” (state 1), “symptom” (state 2) and “death” (state 3), as shown in Figure 1.  
Participants without symptoms could develop symptoms (transition from “no symptom” 
to “symptom”, p12) or remain without symptoms (transition from “no symptom” to “no 
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symptom”, p11). Participants with symptoms could recover from their symptom 
(transition from “symptom” to “no symptom”, p21) or symptoms could persist (transition 
from “symptom” to “symptom”, p22). In addition, transitions to the absorbing death 
state are possible from the “symptom” state as well as the “no symptom” state. The use 
of history of the BPS in the model relaxes the first order Markov assumption and means 
the model is a semi-Markov model. 
 
The maximum likelihood estimates and transition rates with 95% confidence intervals 
were calculated. Age at the time of interview was used as the time variable and was 
therefore taken into account in all models. Hazard ratios of the association between 
covariates (sex, baseline MMSE and baseline dementia) and the transitions between 
states were calculated. In a semi-Markov model, the association between BPS history and 
transition between states was analysed in those with two or more interviews. A 
sensitivity analysis was performed using BPS definitions based on participant information 
only. Data cleaning and descriptive analyses were completed using Stata 12.0, followed 
by analysis using R version 2.15.3 (R Development Core Team 2010) and the “msm” 
package in R (Jackson 2011). 
 
[Figure 1] 
 
Missing data  
 
Interviews where the BPS symptom sections were not administered were excluded from 
analysis. Other interviews for these participants were included in the analysis, except 
when excluding the interview with missing data resulted in the participant having only a 
single interview, in which case the participant was excluded.  
 
 
Results 
 
Baseline characteristics 
 
At baseline, 3,626 participants were included. The mean age was 81.4 years, ranging from 
65 to 105, and approximately two thirds of the population were women. As we excluded 
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those with a MMSE score above 25, all participants had cognitive impairment: 37% had 
low cognitive function (MMSE 0-18), 28% moderate (MMSE 19-22) and 35% high (MMSE 
23-25). In addition, 37% had dementia at baseline (62% of those with MMSE 0-18, 16% of 
those with MMSE 19-22, and 5% of those with MMSE 23-25). 
 
The prevalence of BPS at the first interview with dementia where symptom presence is 
not missing is shown in Online Additional Table 1 and 2. More details on the prevalence 
of BPS in MRC-CFAS have been previously reported in those with and without dementia 
(Savva et al. 2009; van der Linde et al. 2010). Sleep problems and apathy have the highest 
prevalence and are seen in 43.1% and 31.9% of the population at baseline respectively. 
Irritability was also common (baseline prevalence 21.6%), whereas psychotic symptoms 
were less often seen (baseline prevalence hallucination 9.2%).   
 
 
Flowchart of symptoms over time 
 
Online Additional Table 3 shows the presence of symptoms, the number of missing 
values, loss to follow-up and drop out due to death across the interviews. Figure 2 shows 
the simplified flow chart of the presence of apathy over the 10 year follow-up period. The 
full flowchart that includes the number of missing values over time is available online 
(Online Additional Figure 2).  Apathy was selected as an example because of its high 
prevalence (31.9%, see Online Additional Table 1) which is consistent with findings in the 
literature that suggest it has a high incidence and prevalence,  although its longitudinal 
course has not been studied frequently (systematic review under review with the British 
Journal of Psychiatry). The number of transitions for each of the symptoms is available 
online (Online Additional Table 4). 
 
The figure suggests that apathy is stable. Participants with apathy seem more likely to 
report apathy again at the next interview than the people without apathy. For example, 
of the people with apathy at the first interview, 189 (16.7%) report apathy at the next 
interview, compared to 155 (13.7%) who do not. Of those without apathy at the first 
interview, 813 (33.6%) do not report apathy at the next interview, compared to 244 
(10.1%) who do report apathy. During follow-up, 3,162 participants died and 392 were 
lost to follow-up. Those who died seem more likely to have reported apathy at the last 
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interview before death. Across all interviews, 1,235 (67.7%) of the people who reported 
apathy had died at the next interview, compared to 1,927 (50.4%) of those who did not 
report apathy.  
 
 [Figure 2] 
 
One year transition rates 
 
Table 1 shows the estimated transition rates between the three states “no symptom” 
(state 1), “symptom” (state 2) and “death” (state 3) within one year. For example, a 
typical person without apathy had a probability of 13.5% of having developed apathy one 
year later, a probability of 76.3% of still not having apathy, and a probability of 10.2% of 
dying. A typical person with apathy had a probability of 62.2% of still having apathy one 
year later, a probability of 14.2% of recovering from apathy, and a probability of 23.6% of 
dying. Age is used as the time variable in the model and is the only covariate taken into 
account.  
 
[Table 1] 
 
New symptoms 
Transitions from the “no symptom” state to the “symptom” state were most likely for 
apathy. The probability of developing apathy was 13.5%. The transition rates for 
emergence of new symptoms generally reflect the prevalence of symptoms, with 
symptoms with a high prevalence such as apathy, sleep problems and depression 
showing high transition rates, and symptoms with a lower prevalence such as anxiety, 
hallucination and elation showing low transition rates.  
 
Stability of symptoms 
Apathy was one of the most stable symptoms (i.e. a high probability of staying in states 
“symptom” to “symptom”). In those with apathy, the probability of still having apathy 
after 1 year is 62%. For most other symptoms the one year stability ranges between 35% 
and 45%, while persecution, sleep problems and elation are not as stable. Wandering and 
misidentification also show a high stability.  
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Mortality 
For all symptoms except sleep problems the probability of dying is higher in those with 
the symptom than in those without. Table 2 shows the hazard ratios of the one-year 
transitions to death for those with the symptom compared to those without. Those with 
apathy or misidentification showed the highest mortality risk. Mortality is 3.1 times more 
likely in those with apathy than in those without apathy.  
 
[Table 2] 
 
Association between covariates and the transition ratios 
 
Table 3 gives the estimated hazard ratios for the association between covariates and the 
transition rates.  
 
Sex  
Sex is not associated with symptom emergence or recovery, except for misidentification, 
where women are more likely to develop the symptom. For all symptoms there was a 
suggestion of a lower mortality risk for women mimicking the non symptom difference.   
 
Baseline cognitive function 
Some symptoms appear to be more likely to develop in those with low cognitive function 
compared to those with moderate cognitive function, including apathy, irritability, 
agitation, hallucination, persecution, misidentification and elation. Other symptoms, 
including depression, anxiety and wandering appear to be less likely to develop in those 
with low cognitive function. Significance is only reached for apathy and misidentification. 
For all symptoms, lower cognitive function is associated with mortality.  
 
Dementia at baseline 
All symptoms except anxiety and wandering are more likely to develop in people with 
baseline dementia. Some symptoms appeared to be more stable in dementia and have a 
lower recovery rate, including irritability, persecution, misidentification and elation, 
although these results are only significant for irritability. For most symptoms there is 
some evidence of a higher mortality risk for those with dementia.  
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[Table 3] 
 
Symptom history 
 
Online Additional Table 5 shows the results of a semi-Markov model taking into account 
symptom history for participants with at least two interviews. All symptoms are more 
likely to develop in those who have reported the symptom in previous interviews. For 
some symptoms, including apathy, hallucination and elation, there also appears to be an 
increased mortality risk in those who did not report the symptom at the last interview 
before death, but who have reported the symptom in previous interviews. 
 
Sensitivity analysis  
 
A sensitivity analysis was performed using BPS definitions based on participant interviews 
only. Participant interviews were conducted on a larger number of participants than 
those with additional informant interviews and therefore larger numbers are available 
(n=5,235 compared to n=3,626). The overall results and the association with mortality are 
similar to the results using both participant and informant information, although the 
prevalence, emergence of new symptoms and symptom stability are lower as the 
participant definitions are based on less information (Online Additional Table 6). 
 
 
Discussion 
 
Summary of findings  
 
This study is important because it presents data from a large population-based sample 
with follow-up over a decade. The analyses presented here show that most BPS were 
persistent (wandering, apathy, misidentification, depression and anxiety showed the 
highest persistence), that some symptoms were more likely to develop than others 
(apathy, sleep problems, depression, irritability and wandering were most likely to 
develop), and that BPS are associated with mortality. Low cognitive function and 
dementia were associated with emergence of new symptoms.  
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Apathy 
 
Apathy showed a high prevalence, a high persistence (62%), a high emergence of new 
symptoms (14%) and a strong association with mortality. This is in agreement with the 
literature, although only a limited number of studies are available (Aalten et al. 2005; 
Wetzels et al. 2010).  
 
Apathy has been defined as a disorder of motivation (Marin 1991; Robert et al. 2009; 
Starkstein et al. 2001) and is evidenced by diminished goal-directed overt behaviour, 
diminished goal-directed cognition, and diminished emotional concomitants of goal-
directed behaviour. Here, apathy is defined using participant-based questions on slowing 
of thinking and talking, being less decisive and loss of energy and interest, and informant-
based questions on loss of energy and interest and giving up a special skill or hobby 
(Savva et al. 2009) While less detail is included than in apathy-specific instruments (e.g. 
Apathy Evaluation Scale), the measurement of apathy used here includes questions of all 
three domains of the apathy definition by Marin et al. The Neuropsychiatric Inventory 
(Cummings et al. 1994), the most commonly used instrument to measure BPS, defines 
apathy as a loss of interest. Loss of interest was also included in the definition used here, 
but we also included questions on the slowing of thinking and talking and being less 
decisive which are not included in the NPI. 
 
Symptoms of apathy and depression overlap and the two disorders can be difficult to 
distinguish. Apathy and depression frequently occur together, but both can occur in 
absence of the other. The issue is still under debate, but mostly apathy is considered a 
separate syndrome (Starkstein et al. 2005; Tagariello et al. 2009). The different pattern 
and stability of apathy and depression found here support the view that apathy is a 
separate syndrome.  
 
The high prevalence and high stability of apathy and its associations with disability, 
poorer health and caregiver stress mean that apathy can be a large burden. Apathy is 
associated with disability (Benoit et al. 2008; Freels et al. 1992; Starkstein et al. 2006) and 
people with apathy may rely on others to initiate behaviour even when they are still 
capable of performing the activity (Landes et al. 2001). Apathy is associated with poorer 
physical health, self-neglect, poor nutrition and poor medication adherence and can 
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complicate the management of other conditions including dementia (Benoit et al. 2008), 
diabetes (Padala et al. 2008) and cardiovascular disease (Mayo et al. 2009; Starkstein et 
al. 1993). In addition, apathy can increase caregiver burden (Hart et al. 2003; Kaufer et al. 
1998; Pang et al. 2002; Thomas et al. 2001). Apathy may also reduce quality of life of the 
patient (Samus et al. 2005); although it has been suggested that apathy may not be a 
concern to the patient themselves and has been associated with lack of awareness in 
dementia (Aalten et al. 2006; Derouesne et al. 1999).  
 
All BPS were associated with mortality. The strongest association was found for apathy 
(HR=3.1, 95% CI 2.7-3.7) because of the low risk of death in those without apathy (10.2% 
compared to 13.2-17.7% for the other symptoms).  This low risk of death in those without 
apathy might be explained by the high prevalence and stability of apathy. Participants are 
less likely to have one of the less prevalent symptoms before death. Apathy might be 
associated with mortality because of its associations with physical health and self-neglect 
as described in the previous paragraph, or those with apathy or other BPS may have 
certain neurobiological changes associated with mortality. Conversely, people who lack 
apathy are likely to be physically and socially more active. They are presumably more 
motivated to take care of themselves, eat well and comply with prescribed medication. 
This is likely to be associated with better health and lower mortality. 
 
Apathy may often be overlooked clinically because unlike other symptoms, such as 
irritability, it is less obtrusive to carers and professional staff. However, its association 
with a range of poor outcomes suggests that it should be a more active target for therapy 
and research. For example, the alerting properties of cholinesterase inhibitors may be 
helpful, or perhaps interventions aimed at increasing physical activity and cognitive 
stimulation should be encouraged.  
 
Strengths and limitations 
 
The main strengths of this study are the population-based recruitment of participants, 
the large sample size and the long (10 years) follow-up period. Eleven BPS were studied, 
including apathy and elation. Sensitivity analyses showed similar results and the model 
reproduced well known associations between male sex and mortality and between lower 
cognitive function and mortality. 
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This study adds to the literature by studying the symptoms over a longer time period, 
measuring BPS every two or four years. Using a multistate model made it possible to take 
into account estimations of the probability of transitions that occurred in the time 
between interviews. 
 
BPS history was not measured at baseline and the association between BPS history and 
transition rates could only be studied in those with at least two interviews.  
 
As in all longitudinal studies, loss to follow-up is a challenge. It has previously been shown 
that individuals who refused to participate in the 2 year follow-up interview were more 
likely to have poorer cognitive function, to have less education, and to live in alone in one 
of the rural centres. Those who moved away or were uncontactable were more likely to 
be single, smokers or depressed or to have dementia (Matthews et al. 2004). As several 
of these factors have been associated with presence of BPS and mortality, results might 
have been different if these participants could have been included in the analyses.  
 
It would have been interesting to compare our results in those with a MMSE score below 
25 to those with a diagnosis of dementia. However, this was not possible because of the 
relatively low number of people with dementia and their reduced survival. In addition, 
cognitive function severity bands (MMSE 0-18, 19-22 and 23-25) were based on previous 
analysis in MRC CFAS that compared the predictive probability of each MMSE score to 
detect those who develop dementia in 2 years (Huppert et al. 2005; Matthews et al. 
2008; Stephan et al. 2010). Such groups, based on cognitive test scores, are not perfectly 
matched to the detection of dementia, though obviously the lower band of MMSE scores 
is likely to contain a high proportion of people with dementia. Furthermore, the 
difference between the low MMSE group (upper band: 18) and the high MMSE group 
(lower band: 23) may in some cases be as little as 5 points. It may also be that the 
persistence of BPS differs between these MMSE groups, particularly in the most severely 
impaired (MMSE 0-18) and in those with dementia (37% of the study population). It 
should also be borne in mind that a MMSE score below 25 does not necessarily imply that 
the individual has cognitive impairment and some individuals may have been 
misclassified. 
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We cannot exclude residual confounding. Age has been taken into account in all models, 
and the associations with baseline cognitive function, baseline dementia and BPS history 
have been investigated. Dementia and cognitive function were taken into account at 
baseline only, as using covariate information from all interviews would make the model 
too complex. A range of other factors have been associated with BPS, cognitive function 
and mortality and may have confounded the results, including disability, physical health, 
education, social class, social relationships, treatment and antipsychotic use and 
comorbidity.  
 
 
Conclusion 
 
This population-based, multi-centre study with a follow-up period of 10 years showed 
that BPS are associated with mortality and most symptoms were persistent. Apathy was 
characterised by a high prevalence, a high persistence and a strong association with 
mortality, and it has a negative impact on disability, management of other diseases and 
caregiver burden.   
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Figures 
 
Figure 1 Transition between states 
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Figure 2 Flowchart of the presence of apathy over time 
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Transitions between states: 
 
   To  
From       Lost     No apathy    Apathy    Death 
No apathy   332  1184        381      1927 
Apathy       60   220        310      1235 
 
 
 Tables  
 
Table 1 One year transition rates taking into account age only  
 
 No symptom to 
symptom (p12)  
% (95%CI) 
No symptom to  
no symptom (p11) 
% (95%CI) 
Symptom to symptom 
(p22) 
% (95%CI) 
Symptom to no 
symptom (p21) 
% (95%CI)  
No symptom to death 
(p13)  
% (95%CI) 
Symptom to death (p23)  
 
% (95%CI) 
Apathy 13.5  (12.2 - 15.0) 76.3  (74.9 - 77.5) 62.2  (59.9 - 64.4) 14.2  (12.4 - 16.2) 10.2  (9.5 - 11.1) 23.6  (22.2 - 24.8) 
Depression 5.6  (4.7 - 6.5) 81.7  (80.7 - 82.6) 46.7  (42.1 - 51.0) 36.7  (32.3 - 41.2) 12.8  (12.2 - 13.3) 16.6  (14.6 - 19.0) 
Anxiety 2.6  (2.1 - 3.3) 83.2  (82.3 - 83.9) 43.2  (35.9 - 50.3) 39.7  (32.4 - 47.2) 14.2  (13.6 - 14.8) 17.1  (13.9 - 21.7) 
Irritability 5.5  (4.7 - 6.5) 80.1  (78.9 - 81.3) 33.7  (28.7 - 39.1) 46.7  (40.5 - 52.1) 14.4  (13.8 - 15.0) 19.6  (17.5 - 22.1) 
Agitation 3.6  (2.9 - 4.4) 82.9  (82.0 - 93.7) 35.6  (28.4 - 42.7) 44.8  (37.7 - 52.6) 13.5  (13.0 - 14.1) 19.6  (16.8 - 23.4) 
Hallucination 2.9  (2.3 - 3.5) 82.5  (81.7 - 83.2) 40.7  (34.9 - 46.0) 39.7  (33.9 - 45.9) 14.6 (14.1 - 15.2) 19.6  (16.9 - 23.4) 
Persecution 2.0  (1.5 - 2.7) 83.4  (82.6 - 84.1) 22.7  (13.5 - 32.8) 58.1  (46.3 - 68.8) 14.6  (14.1 - 15.1) 19.1  (16.3 - 23.4) 
Misidentification 3.5  (2.9 - 4.2) 83.3  (82.5 - 94.0) 49.5  (43.8 - 55.0) 20.0  (15.3 - 25.3) 13.2 (12.7 - 13.8) 30.5  (27.6 - 33.8) 
Sleep problems 9.1  (7.5 - 10.8) 75.8  (74.0 - 77.5) 27.8  (22.6 - 33.4) 57.4  (51.1 - 62.9) 15.1 (14.5 - 15.7) 14.8  (13.5 - 16.4) 
Wandering 4.5  (3.2 - 6.5) 80.7  (78.8 - 82.0) 67.3  (61.0 - 72.1) 7.5  (4.1 - 14.2) 14.8 (13.9 - 15.9) 25.2  (21.7 - 28.9) 
Elation 1.6  (1.1 - 2.1) 83.7  (83.0 - 84.4) 27.3  (18.1 - 37.3) 53.7  (42.7 - 63.4) 14.7 (14.2 - 15.2) 19.1  (14.9 - 25.2) 
 
CI, confidence interval 
 
Age is used as the time variable in the model and is the only covariate taken into account. Please see Table 3 for the hazard ratio of the association between covariates and 
transition rates 
Table 2 One-year mortality risk of those with a symptom compared to those without  
 
 Estimation of the ratio of the mortality 
rates for those with the symptom and 
those without the symptom  
Hazard ratio (95%CI) 
Apathy 3.1 (2.7-3.7) 
Depression 1.5 (1.2-1.8) 
Anxiety 1.3 (0.9-1.9) 
Irritability 1.7 (1.4-2.1) 
Agitation 1.8 (1.4-2.3) 
Hallucination 1.5 (1.2-2.0) 
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CI, confidence interval 
 
Age is used as the time variable in the model and is the only covariate taken into account. Please see Table 3 for the hazard ratio of the association between covariates and transition rates
Persecution 1.6 (1.2-2.2) 
Misidentification 3.0 (2.5-3.5) 
Sleep problems 1.0 (0.8-1.2) 
Wandering 1.9 (1.5-2.4) 
Elation 1.6 (1.0-2.4) 
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Table 3 Hazard ratio of the association between covariates and transition rates 
  
 Sex MMSE at baseline Dementia at 
baseline 
 Female vs. Male 0-18 vs. 19-22  23-25 vs. 19-22   Dem vs. no dem  
 HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI) 
Apathy              
No symptom to symptom (p12)  1.0  (0.8 - 1.3) 1.6  (1.2 - 2.2) 0.8  (0.6 - 1.1) 2.3  (1.6 - 3.2) 
Symptom to no symptom (p21) 0.9  (0.6 - 1.3) 0.9  (0.6 - 1.3) 1.3  (0.9 - 1.9) 0.9  (0.6 - 1.4) 
No symptom to death (p13)  0.7  (0.6 - 0.9) 1.9  (1.4 - 2.5) 0.6  (0.4 - 0.8) 2.6 (2.0 - 3.3) 
Symptom to death (p23)  0.9  (0.8 - 1.1) 1.4  (1.2 - 1.7) 1.1  (0.9 - 1.4) 1.5  (1.3 - 1.7) 
Depression                 
No symptom to symptom (p12)  1.2  (0.8 - 1.8) 0.7  (0.4 - 1.2) 0.7  (0.4 - 1.0) 0.7  (0.5 - 1.2) 
Symptom to no symptom (p21) 1.2  (0.8 - 1.9) 1.1  (0.7 - 1.6) 1.0  (0.6 - 1.5) 1.3  (0.9 - 1.9) 
No symptom to death (p13)  0.9  (0.8 - 1.0) 1.8  (1.6 - 2.1) 0.7  (0.6 - -0.8) 2.0  (1.8 - 2.3) 
Symptom to death (p23)  0.7  (0.5 - 1.0) 1.6  (1.0 - 2.7) 1.3  (0.8 - 2.3) 1.1  (0.8 - 1.7) 
Anxiety                 
No symptom to symptom (p12)  1.1  (0.6 - 2.1) 0.7  (0.4 - 1.5) 0.9  (0.4 - 1.7) 0.9  (0.4 - 1.9) 
Symptom to no symptom (p21) 0.9  (0.5 - 1.6) 1.1  (0.6 - 2.0) 1.3  (0.7 - 2.6) 1.2  (0.7 - 2.1) 
No symptom to death (p13)  0.8  (0.7 - 0.9) 1.8  (1.6 - 2.0) 0.7  (0.6 - 0.8) 2.3  (2.1 - 2.5) 
Symptom to death (p23)  1.1  (0.5 - 2.1) 0.9  (0.4 - 2.1) 1.1  (0.4 - 2.6) 0.8  (0.4 - 1.7) 
Irritability                 
No symptom to symptom (p12)  0.9  (0.5 - 1.4) 1.4  (0.6 - 3.0) 0.7  (0.4 - 1.1) 2.2  (1.2 - 3.9) 
Symptom to no symptom (p21) 0.9  (0.6 - 1.5) 1.7  (0.8 - 3.4) 0.9  (0.5 - 1.5) 0.4  (0.2 - 1.0) 
No symptom to death (p13)  0.9  (0.8 - 1.0) 1.9  (1.7 - 2.2) 0.7  (0.6 - 0.8) 1.1  (0.9 - 1.4) 
Symptom to death (p23)  0.7  (0.5 - 1.0) 1.3  (0.8 - 2.3) 1.1  (0.7 - 2.0) 1.1   (0.8 - 1.7) 
Agitation                 
No symptom to symptom (p12)  1.1  (0.6 - 1.9) 1.5  (0.7 - 3.2) 0.7  (0.3 - 1.7) 2.3  (1.1 - 4.7) 
Symptom to no symptom (p21) 1.0  (0.6 - 1.9) 0.8  (0.4 - 1.7) 1.0  (0.4 - 2.2) 1.2  (0.6 - 2.3) 
No symptom to death (p13)  0.9  (0.8 - 1.0) 1.8  (1.6 - 2.0) 0.8  (0.7 - 0.9) 2.3  (2.1 - 2.6) 
Symptom to death (p23)  0.9  (0.5 - 1.5) 1.5  (0.7 - 3.1) 0.5  (0.2 - 1.6) 1.4  (0.7 - 2.9) 
Hallucination                 
No symptom to symptom (p12)  1.3  (0.8 - 2.2) 1.2  (0.7 - 2.3) 0.7  (0.3 - 1.3) 1.8  (0.5 - 2.9) 
Symptom to no symptom (p21) 1.0  (0.7 - 1.7) 0.8  (0.5 - 1.3) 0.9  (0.5 - 1.6) 1.1  (0.7 - 1.7) 
No symptom to death (p13)  0.8  (0.8 - 0.9) 1.8  (1.6 - 2.0) 0.7  (0.6 - 0.8) 2.3  (2.1 - 2.5) 
Symptom to death (p23)  0.9  (0.6 - 1.5) 1.5  (0.7 - 3.4) 1.7  (0.7 - 4.3) 1.7  (1.0 - 2.9) 
Persecution                 
No symptom to symptom (p12)  1.2  (0.5 - 3.0) 2.0 (0.6 - 7.0) 0.6  (0.2 - 2.0) 2.8  (0.9 - 8.4) 
Symptom to no symptom (p21) 1.0  (0.5 - 2.1) 0.7  (0.2 - 1.9) 1.0  (0.4 - 2.7) 0.7  (0.3 - 1.8) 
No symptom to death (p13)  0.8  (0.8 - 0.9) 1.8  (1.6 - 1.9) 0.7  (0.7 - 0.8) 2.2  (2.0 - 2.4) 
Symptom to death (p23)  0.9  (0.5 - 1.7) 2.7  (0.8 - 8.7) 1.0  (0.1 - 7.4) 2.2  (0.9 - 5.5) 
Misidentification                 
No symptom to symptom (p12)  1.8  (1.1 - 3.0) 2.8  (1.5 - 5.1) 0.6  (0.3 - 1.3) 5.1  (3.0 - 8.9) 
Symptom to no symptom (p21) 0.9  (0.5 - 1.6) 0.6  (0.3 - 1.3) 0.8  (0.3 - 1.7) 0.8  (0.4 - 1.5) 
No symptom to death (p13)  0.7  (0.7 - 0.8) 1.5  (1.3 - 1.8) 0.7  (0.6 - 0.8) 2.0  (1.7 - 2.3) 
Symptom to death (p23)  1.1  (0.8 - 1.5) 1.9  (1.1 - 3.3) 1.6  (0.8 - 3.2) 1.3  (0.9 - 1.8) 
Sleep problems                 
No symptom to symptom (p12)  1.5  (0.8 - 2.8) NA  -  NA  -  1.7  (0.8- - 3.5) 
Symptom to no symptom (p21) 1.2  (0.8 - 1.0)   -    -  1.1  (0.6- - 1.9) 
No symptom to death (p13)  0.9  (0.8 - 1.0)   -    -  2.1  (0.6- - 1.9) 
Symptom to death (p23)  0.5 (0.4 - 0.8)   -    -  3.0  (1.9- - 4.7) 
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Table 3 continued 
 
Wandering                 
No symptom to symptom (p12)  1.0  (0.4 - 2.3) 0.6 (0.2 - 1.7) 0.9 (0.3 - 2.4) 0.6 (0.0 - 7.2) 
Symptom to no symptom (p21) 0.9  (0.2 - 4.1) 1.1 (0.2 - 6.3) 0.7 (0.1 - 6.7) 1.2 (0.0 - 27.8) 
No symptom to death (p13)  0.8  (0.7 - 1.0) 2.1 (1.5 - 2.8) 0.6 (0.3 - 1.1) 1.5 (1.0 - 2.1) 
Symptom to death (p23)  0.9  (0.6 - 1.4) 1.0 (0.6 - 1.6) 1.2 (0.6 - 2.2) 0.7 (0.3 - 1.7) 
Elation                 
No symptom to symptom (p12)  1.2  (0.4 - 3.3) 2.2 (0.8 - 6.1) 0.5 (0.2 - 1.4) 2.7 (1.1 - 6.4) 
Symptom to no symptom (p21) 0.6  (0.3 - 1.4) 1.2 (0.5 - 2.9) 0.9 (0.4 - 2.0) 0.8 (0.4 - 1.6) 
No symptom to death (p13)  0.9  (0.8 - 1.0) 1.8 (1.6 - 2.0) 0.7 (0.7 - 0.8) 2.2 (2.2 - 2.4) 
Symptom to death (p23)  0.6  (0.2 - 1.4) 4.4 (0.6 - 29.2) 0.4 (0.0 - 13.3) 3.0 (3.0 - 9.8) 
 
  
NA Too few transitions to model, model does not converge 
CI, confidence interval 
MMSE, mini mental state examination 
Dem, dementia 
 
